Serum ALT, AST and AP levels (WT, n = 7; Mdr2 −/− , n = 9; WT + DSS, n = 6; Mdr2 −/− + DSS, n = 10) from 2 representative independent cohorts; one-way ANOVA with Bonferroni’s multiple comparison test (ALT: WT vs Mdr2 −/− , 95% CI −645.6 to −399, P < 0.0001; Mdr2 −/− vs Mdr2 −/− + DSS, 95% CI 234.5–459.3, P < 0.0001; WT + DSS vs vs Mdr2 −/− + DSS, 95% CI −317 to −64.35, P = 0.0016; AST: WT vs Mdr2 −/− , 95% CI −617.5 to −360.9, P < 0.0001; Mdr2 −/− vs Mdr2 −/− + DSS, 95% CI 231.8 to 465.8, P < 0.0001; WT + DSS vs vs Mdr2 −/− + DSS, 95% CI −284.7 to −21.68, P = 0.0171; AP: WT vs Mdr2 −/− , 95% CI −638.1 to −437, P < 0.0001; Mdr2 −/− vs Mdr2 −/− + DSS, 95% CI 323.9–507.2, P < 0.0001; WT + DSS vs vs Mdr2 −/− + DSS, 95% CI −284.2 to −78.16, P = 0.0003).
